leisure time -WSS

leisure time

author：entertainment 2025-10-01 17:35:30 - browse：22

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Supreme Court strikes down use of affirmative action

WSS

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Activists slam private health insurers over coverage restrictions

Industry veterans launch new biotech VC with $310M

To avoid data mishandling cases, universities eye AI and other tools

How to save PrEP access — and even expand it

How digital tools helped lower hypertension in marginalized patients

explore

leisure time

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

ChatGPT in medicine: STAT answers readers' burning questions

The dental labor crisis is a moment of opportunity

As demand for Covid shots wanes, Moderna seeks its next success

Trump demands the U.S. pay no more for drugs than other countries … again

At least 13 dead in Texas as scorching temps continue

Anesthesiologist group: stop taking Ozempic before surgery

Malaria cases in Florida and Texas: Here’s what you need to know

In Memoriam: Notable people who died in 2023

leisure time

Vaccine advisory panel ACIP left half staffed by HHS

BioMarin wins approval for gene therapy to treat hemophilia A

Affirmative action in medical school literally saved lives

KalVista pill reduced swelling 'attacks' caused by genetic disease

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

focus

knowledge

entertainment

focus